$30 Billion Deal, page-4097

@psuedoname1 - sorry, the reply function is not working.

OK - but I am not sure where you think I'm wrong in any assessment I made. Like everyone here - we don't have much information to work on at the moment.

Yes, trial analysis can be complex - but to a degree. It either attains its end goals or it doesn't. The small differentiations are what further analysis looks at. At this point, a lot of the complexity goes as the area of what is being concentrated on is more limited. That should actually have been completed by now.

I did not see any difference in tone at the quarterly - if anything, maybe a bit more cautious in wording.If nothing else, BIT should give some sort of update which goes beyond "in coming weeks" - a bit more meat this time around.

Otherwise they are looking a bit incompetent. As the contracting party, they should have much more control on what the labs are doing and the time that is required to get some meaningful data.